Sanofi India Limited has released the complete transcript of its investor/analysts call held on February 26, 2026, discussing financial results for Q4FY26 and the year ended December 2025. The pharmaceutical company submitted the transcript to stock exchanges on March 5, 2026, following the earlier upload of the video recording.

Regulatory Compliance and Documentation

The transcript submission was made pursuant to Regulation 30 read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The communication was signed by Haresh Vala, Company Secretary & Compliance Officer (Membership No: A18246), and digitally authenticated on March 5, 2026, at 15:31:40 +05'30'.

Management Participation

The investor conference call was attended by key management personnel including Mr. Deepak Arora (Managing Director), Mr. Rachid Ayari (Whole-Time Director and Chief Financial Officer), and Mr. Haresh Vala (Company Secretary). The call was moderated and included a comprehensive Q&A session with investors and analysts.

Key Discussion Areas

The transcript reveals detailed discussions on the company's business transformation journey, financial performance, and strategic initiatives. Management highlighted the pivotal transformation undertaken to modernize the business model, positioning the company as an R&D-driven, AI-enabled biopharma organization with focus on patient centricity and digital capabilities.

Accessibility and Transparency

Both the video recording and transcript are now available on Sanofi India's official website in the Analyst/Investor Meet section, ensuring comprehensive access to stakeholders. This dual documentation approach demonstrates the company's commitment to transparency and regulatory compliance in investor communications.

Sanofi India Limited has published its audited financial results for the quarter and year ended December 31, 2025, in leading newspapers including Business Standard and Sakal. The pharmaceutical company's results reveal mixed performance with declining overall revenue but strong growth in its core diabetes franchise.

Financial Performance Overview

The company's financial results show a challenging year with total income from operations declining 9% year-over-year to ₹18,571 million in FY25 from ₹20,297 million in FY24. This decline was primarily attributed to reduced export sales, which dropped significantly by 40% to ₹2,244 million from ₹3,725 million in the previous year.

Quarterly Performance Analysis

The Q4 FY25 quarterly results showed total income from operations at ₹4,226 million compared to ₹5,208 million in Q4 FY24, representing a decline from the previous year. Net profit before tax and exceptional items for the quarter stood at ₹830 million, while net profit after tax was ₹617 million.

Earnings Per Share and Dividend Distribution

The company's earnings per share for FY25 improved to ₹141.85 from ₹136.21 in the previous year, reflecting better profitability despite revenue challenges. The board has proposed a 5% increase in total dividend for 2025, with the total dividend per share standing at ₹123, comprising an interim dividend of ₹75 and a recommended final dividend of ₹48 per equity share.

Strategic Business Transformation

The company continues its strategic transformation focusing on two key pillars: growing the insulin franchise with customer-centric, digitally and AI-empowered capabilities, and implementing a partnership model for the legacy portfolio in cardiovascular, central nervous system, and oral antidiabetic segments. The diabetes portfolio demonstrates strong market positioning with Lantus maintaining a 31% market share and achieving 6% volume acceleration.

Operational Excellence and Cost Management

Sanofi India achieved significant operational efficiency with a 17% reduction in operating expenses for the full year. Total operating expenses decreased to ₹4,489 million from ₹5,431 million in FY24, driven by business optimization and operational expense efficiency measures. Employee costs were reduced by 23% to ₹1,853 million, while other operating expenses declined by 13% to ₹2,636 million.

The financial results were reviewed by the Audit Committee on February 24, 2026, and approved by the Board of Directors on February 25, 2026. The complete financial results are available on BSE, NSE, and the company's official website.